News-Medical.Net on MSN

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
CURE

FDA Accepts Ivonescimab Application for EGFR Lung Cancer

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...
Healthcare Asia Magazine on MSN

A*STAR disarms pathway protecting lung cancer cells

The discovery addresses resistance amongst patients after one to two years of treatment. Researchers at Agency for Science, ...
Targeted Oncology

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
Business Wire

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 phase 2 trial and supported by data from additional trials including TROPION-Lung01 Previously submitted BLA based on ...
News9

Could a daily pill after chemoradiation keep lung cancer from returning?

A daily pill called osimertinib (Tagrisso) is delivering far longer cancer control for adults with unresectable stage 3 EGFR-mutated non-small cell lung cancer after chemoradiation and is now ...
Seeking Alpha

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

CHENGDU, China and SEATTLE and LONDON, May 13, 2022 /PRNewswire/ -- BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced today that it ...